DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients.
| Molecular Weight | 356.42 |
| CAS Number | 2242470-43-3 |
| Solubility (25°C) | DMSO 62.5 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related NF-κB Products |
|---|
| Narlumosbart
Narlumosbart is a human IgG4ҡ monoclonal antibody (mAb) that targets Receptor Activating Factor for Nuclear Factor κB Ligand (RANKL) and can be used in studies related to Giant Cell Tumor of Bone (GCTB). |
| Ac2-26
Ac2-26, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. |
| Mitogen-activated protein kinase 1
Mitogen-activated protein kinase 1 (MAPK1) can activate the downstream p38/NF-κB pathway. |
| IKKγ NBD Inhibitory Peptide
IKKγ NBD Inhibitory Peptide is a highly specific inhibitor NF-κB inhibitor. |
| Tripeptide-41
Tripeptide-41(CG-Lipoxyn)isa bioactive peptide withreduce fat accumulationeffect and has been reported used as a cosmetic ingredient. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
